Circulatory miRNAs as Correlates of Elevated Intra-Pancreatic Fat Deposition in a Mixed Ethnic Female Cohort: The TOFI_Asia Study

Ectopic lipid accumulation, including intra-pancreatic fat deposition (IPFD), exacerbates type 2 diabetes risk in susceptible individuals. Dysregulated circulating microRNAs (miRNAs) have been identified as correlating with clinical measures of pancreatitis, pancreatic cancer and type 1 diabetes. The aim of the current study was therefore to examine the association between circulating abundances of candidate miRNAs, IPFD and liver fat deposition as quantified using magnetic resonance imaging (MRI) and spectroscopy (MRS). Asian Chinese (n = 34; BMI = 26.7 ± 4.2 kg/m2) and European Caucasian (n = 34; BMI = 28.0 ± 4.5 kg/m2) females from the TOFI_Asia cohort underwent MRI and MRS analysis of pancreas (MR-%IPFD) and liver fat (MR-%liver fat), respectively, to quantify ectopic lipid deposition. Plasma miRNA abundances of a subset of circulatory miRNAs associated with IPFD and liver fat deposition were quantified by qRT-PCR. miR-21-3p and miR-320a-5p correlated with MR-%IPFD, plasma insulin and HOMA2-IR, but not MR-%liver fat. MR-%IPFD remained associated with decreasing miR-21-3p abundance following multivariate regression analysis. miR-21-3p and miR-320a were demonstrated to be negatively correlated with MR-%IPFD, independent of ethnicity. For miR-21-3p, this relationship persists with the inclusion of MR-%liver fat in the model, suggesting the potential for a wider application as a specific circulatory correlate of IPFD.

[1]  C. Luchini,et al.  Pancreatic steatosis and metabolic pancreatic disease: a new entity? , 2023, Internal and Emergency Medicine.

[2]  E. Golemis,et al.  Intrapancreatic fat, pancreatitis, and pancreatic cancer , 2023, Cellular and Molecular Life Sciences.

[3]  Sneha S. Pillai,et al.  Insight into the Inter-Organ Crosstalk and Prognostic Role of Liver-Derived MicroRNAs in Metabolic Disease Progression , 2023, Biomedicines.

[4]  C. Bian,et al.  Identification of key microRNAs in exosomes derived from patients with the severe acute pancreatitis. , 2022, Asian Journal of Surgery.

[5]  J. Ampuero,et al.  Contribution of Liver and Pancreatic Islet Crosstalk to β-Cell Function/Dysfunction in the Presence of Fatty Liver , 2022, Frontiers in Endocrinology.

[6]  K. Hollingsworth,et al.  Pancreas Fat, an Early Marker of Metabolic Risk? A Magnetic Resonance Study of Chinese and Caucasian Women: TOFI_Asia Study , 2022, Frontiers in Physiology.

[7]  Juyeon Ko,et al.  Associations between Intra-Pancreatic Fat Deposition, Pancreas Size, and Pancreatic Enzymes in Health and after an Attack of Acute Pancreatitis , 2021, Obesity Facts.

[8]  K. Fraser,et al.  Untargeted metabolomics reveals plasma metabolites predictive of ectopic fat in pancreas and liver as assessed by magnetic resonance imaging: the TOFI_Asia study , 2021, International Journal of Obesity.

[9]  Yannan Jiang,et al.  Visceral Adiposity and Glucoregulatory Peptides are Associated with Susceptibility to Type 2 Diabetes: The TOFI_Asia Study , 2020, Obesity.

[10]  C. Valério,et al.  NAFLD as a continuum: from obesity to metabolic syndrome and diabetes , 2020, Diabetology & Metabolic Syndrome.

[11]  Hongliang Li,et al.  Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases , 2020, Circulation research.

[12]  F. Hu,et al.  Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. , 2019, The lancet. Diabetes & endocrinology.

[13]  J. Markworth,et al.  Circulatory miRNA biomarkers of metabolic syndrome , 2019, Acta Diabetologica.

[14]  Tao Wang,et al.  MiR-21-3p aggravates injury in rats with acute hemorrhagic necrotizing pancreatitis by activating TRP signaling pathway. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[15]  Liangping Li,et al.  Down‐regulation of microRNA‐375 regulates adipokines and inhibits inflammatory cytokines by targeting AdipoR2 in non‐alcoholic fatty liver disease , 2018, Clinical and experimental pharmacology & physiology.

[16]  G. Al-Kafaji,et al.  Evaluation of Two-Diabetes Related microRNAs Suitability as Earlier Blood Biomarkers for Detecting Prediabetes and type 2 Diabetes Mellitus , 2018, Journal of clinical medicine.

[17]  M. Puzianowska-Kuźnicka,et al.  NGS Reveals Molecular Pathways Affected by Obesity and Weight Loss-Related Changes in miRNA Levels in Adipose Tissue , 2017, International journal of molecular sciences.

[18]  S. Poppitt,et al.  Ectopic fat accumulation in the pancreas and its biomarkers: A systematic review and meta‐analysis , 2017, Diabetes/metabolism research and reviews.

[19]  L. Bouwens,et al.  Circulating microRNA-375 as biomarker of pancreatic beta cell death and protection of beta cell mass by cytoprotective compounds , 2017, PloS one.

[20]  J. Markworth,et al.  Acute resistance exercise modulates microRNA expression profiles: Combined tissue and circulatory targeted analyses , 2017, PloS one.

[21]  M. Stoffel,et al.  MicroRNAs as stress regulators in pancreatic beta cells and diabetes , 2017, Molecular metabolism.

[22]  A. Peters,et al.  Pancreatic fat content by magnetic resonance imaging in subjects with prediabetes, diabetes, and controls from a general population without cardiovascular disease , 2017, PloS one.

[23]  Ke Li,et al.  Circulating miRNA-21-5p as a diagnostic biomarker for pancreatic cancer: evidence from comprehensive miRNA expression profiling analysis and clinical validation , 2017, Scientific Reports.

[24]  Roy Taylor,et al.  Quantification of intrapancreatic fat in type 2 diabetes by MRI , 2017, PloS one.

[25]  L. Plank,et al.  Ectopic fat accumulation in the pancreas and its clinical relevance: A systematic review, meta-analysis, and meta-regression. , 2017, Metabolism: clinical and experimental.

[26]  Z. Liao,et al.  Novel blood-based microRNA biomarker panel for early diagnosis of chronic pancreatitis , 2017, Scientific Reports.

[27]  R. Catanzaro,et al.  Exploring the metabolic syndrome: Nonalcoholic fatty pancreas disease , 2016, World journal of gastroenterology.

[28]  Z. Younossi,et al.  Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease , 2016, BMJ open gastroenterology.

[29]  Yan-ji Luo,et al.  Noninvasive fat quantification of the liver and pancreas may provide potential biomarkers of impaired glucose tolerance and type 2 diabetes , 2016, Medicine.

[30]  M. Foti,et al.  Stress-activated miR-21/miR-21* in hepatocytes promotes lipid and glucose metabolic disorders associated with high-fat diet consumption , 2016, Gut.

[31]  H. Yki-Järvinen,et al.  Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD—A Systematic Review , 2016, International journal of molecular sciences.

[32]  D. Marsh,et al.  Comparison of Methodologies to Detect Low Levels of Hemolysis in Serum for Accurate Assessment of Serum microRNAs , 2016, PloS one.

[33]  R. Vyzula,et al.  MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma , 2015, Diagnostic Pathology.

[34]  Sha Li,et al.  Exosome and Exosomal MicroRNA: Trafficking, Sorting, and Function , 2015, Genom. Proteom. Bioinform..

[35]  P. Linsley,et al.  Disease-linked microRNA-21 exhibits drastically reduced mRNA binding and silencing activity in healthy mouse liver. , 2012, RNA.

[36]  E. Gamazon,et al.  Population differences in microRNA expression and biological implications , 2011, RNA biology.

[37]  J. Timmons,et al.  Gene-chip studies of adipogenesis-regulated microRNAs in mouse primary adipocytes and human obesity , 2011, BMC endocrine disorders.

[38]  Jaimie N. Davis,et al.  Ethnic Differences in Pancreatic Fat Accumulation and Its Relationship With Other Fat Depots and Inflammatory Markers , 2011, Diabetes Care.

[39]  F. Lynn,et al.  Meta-regulation: microRNA regulation of glucose and lipid metabolism , 2009, Trends in Endocrinology & Metabolism.

[40]  Qin-Hui Tuo,et al.  CHANGES IN microRNA (miR) PROFILE AND EFFECTS OF miR‐320 IN INSULIN‐RESISTANT 3T3‐L1 ADIPOCYTES , 2009, Clinical and experimental pharmacology & physiology.

[41]  Charles E. Vejnar,et al.  Integration of microRNA miR-122 in hepatic circadian gene expression. , 2009, Genes & development.

[42]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[43]  H. Pitt,et al.  Nonalcoholic fatty pancreas disease. , 2007, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[44]  R. Unger Lipid overload and overflow: metabolic trauma and the metabolic syndrome , 2003, Trends in Endocrinology & Metabolism.

[45]  D. Dreiling,et al.  Effects of sex and age on pancreatic secretion , 1986, International journal of pancreatology : official journal of the International Association of Pancreatology.

[46]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[47]  D. Gauguier,et al.  Biological roles of microRNAs in the control of insulin secretion and action. , 2017, Physiological genomics.